J Funct Biomater. 2017 Jun 28;8(3). doi: 10.3390/jfb8030024.
Biocompatibility of HbV: Liposome-Encapsulated Hemoglobin Molecules-Liposome Effects on Immune Function.
Journal of functional biomaterials
Hiroshi Azuma, Mitsuhiro Fujihara, Hiromi Sakai
Affiliations
Affiliations
- Department of Pediatrics, Asahikawa Medical University, Asahikawa 078-8510, Japan. [email protected].
- Japanese Red Cross, Hokkaido Block Blood Center, Sapporo 063-0802, Japan. [email protected].
- Department of Chemistry, Nara Medical University, Kashihara 634-8521, Japan. [email protected].
PMID: 28657582
PMCID: PMC5618275 DOI: 10.3390/jfb8030024
Abstract
Hemoglobin vesicles (HbVs) are oxygen carriers consisting of Hb molecules and liposome in which human hemoglobin (Hb) molecules are encapsulated. Investigations of HbV biocompatibility have shown that HbVs have no significant effect on either the quality or quantity of blood components such as RBC, WBC, platelets, complements, or coagulation factors, reflecting its excellent biocompatibility. However, their effects on the immune system remain to be evaluated. HbVs might affect the function of macrophages because they accumulate in the reticuloendothelial system. Results show that splenic T cell proliferation is suppressed after injection of not only HbV but also empty liposome into rat, and show that macrophages that internalized liposomal particles are responsible for the suppression. However, the effect is transient. Antibody production is entirely unaffected. Further investigation revealed that those macrophages were similar to myeloid-derived suppressor cells (MDSCs) in terms of morphology, cell surface markers, and the immune-suppression mechanism. Considering that MDSCs appear in various pathological conditions, the appearance of MDSC-like cells might reflect the physiological immune system response against the substantial burden of liposomal microparticles. Therefore, despite the possible induction of immunosuppressive cells, HbVs are an acceptable and promising candidate for use as a blood substitute in a clinical setting.
Keywords: MDSC; artificial red blood cell; hemoglobin; immune suppression; liposome
Conflict of interest statement
The authors declare no conflict of interest.
References
- J Clin Invest. 2015 Sep;125(9):3356-64 - PubMed
- J Pharmacol Exp Ther. 2011 Apr;337(1):42-9 - PubMed
- Immunopharmacol Immunotoxicol. 2017 Jun;39(3):140-147 - PubMed
- Parasitol Res. 1999 Jul;85(7):594-6 - PubMed
- Methods Enzymol. 2009;465:363-84 - PubMed
- J Immunol. 1991 Apr 15;146(8):2737-46 - PubMed
- J Immunol. 1993 Nov 15;151(10):5492-503 - PubMed
- Bioconjug Chem. 1997 Jan-Feb;8(1):23-30 - PubMed
- Am J Pathol. 2001 Sep;159(3):1079-88 - PubMed
- Sci Transl Med. 2014 Jan 15;6(219):219ra7 - PubMed
- Trends Immunol. 2011 Jan;32(1):19-25 - PubMed
- J Pharmacol Exp Ther. 2005 Feb;312(2):702-9 - PubMed
- Nat Biotechnol. 2012 Dec;30(12):1217-24 - PubMed
- Artif Organs. 2014 Mar;38(3):234-8 - PubMed
- Artif Cells Blood Substit Immobil Biotechnol. 2007;35(2):157-72 - PubMed
- J Intern Med. 2008 Jan;263(1):4-15 - PubMed
Publication Types